FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol

The FDA on July 17 approved the first oral drug in the PCSK9 inhibitor class, a move that could meaningfully change how cardiologists manage patients who can't get their LDL cholesterol under control on statins alone.

The agency cleared Lipfendra (enlicitide), a 20-milligram once-daily tablet made by Merck, for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia, or HeFH. According to the FDA press announcement reviewed by BioSpace, the approval positions Lipfendra as an adjunct to diet and exercise for patients who need further LDL reduction beyond existing therapies.

Until now, every approved PCSK9 inhibitor required a subcutaneous injection given every two to four weeks. That's not nothing for a patient managing a chronic condition. The needle is a real barrier for some people, and adherence to long-term injectable therapies is notoriously uneven outside clinical trials.

What makes an oral version possible here is the drug's molecular structure. According to Pharmacy Times, enlicitide is a macrocyclic peptide, a smaller ring-shaped molecule that the gastrointestinal tract can absorb in meaningful amounts, unlike the large monoclonal antibodies that underpin the injectable PCSK9 agents evolocumab and alirocumab.

The approval was supported by two Phase 3 trials called CORALreef Lipids and CORALreef HeFH. According to a Merck statement reviewed by the American Journal of Managed Care, in those trials enlicitide cut LDL cholesterol by up to roughly 60 percent compared to placebo at 24 weeks. Full results from CORALreef Lipids were published in the New England Journal of Medicine in February 2026.

The efficacy numbers match what the injectable PCSK9 agents deliver, which matters. If a pill performs as well as a shot, the calculus for prescribers and patients shifts considerably, particularly for people with needle aversion, limited access to injection training, or logistical barriers to refrigerating a biologic.

According to Pharmacy Times, Ann Marie Navar, MD, PhD, an associate professor of internal medicine at UT Southwestern Medical Center and a lead CORALreef trial author, described enlicitide as "the most potent oral therapy available after high-intensity statins." That's a meaningful clinical benchmark, given that statins are the backbone of lipid management in most guidelines.

The safety picture, per FDA and Pharmacy Times reporting, was generally similar to placebo across the trials. In the HeFH cohort, diarrhea was reported in about seven percent of participants and dizziness in about nine percent, both figures worth watching in postmarket surveillance for a drug that patients will take daily for years.

One open question for patients and payers alike is price. According to Medical Daily, Merck had not released a list price as of July 20. The existing injectable PCSK9 inhibitors carry list prices in the range of $5,000 to $7,000 annually, though real-world out-of-pocket costs have often been lower with manufacturer assistance programs. Whether Lipfendra lands near, above, or below that band will go a long way toward determining how broadly it's actually used.

According to BioSpace, Lipfendra was approved under the FDA's Commissioner's National Priority Voucher program, an initiative designed to speed reviews for medicines aligned with certain U.S. government priorities. AstraZeneca is developing its own oral PCSK9 candidate, meaning competition in this space may arrive faster than it did in the injectable era.

For the patient sitting across from a cardiologist today, the practical question is straightforward: if a pill works as well as a shot, most people will choose the pill. Adherence in chronic cardiovascular disease management is a clinical problem, not a willpower problem, and format matters more than it's often credited with.

Sources cited:
- FDA press announcement (via BioSpace) (https://www.biospace.com/press-releases/fda-approves-first-oral-pcsk9-inhibitor-to-lower-ldl-cholesterol-in-adults-with-high-cholesterol)
- Pharmacy Times (https://www.pharmacytimes.com/view/fda-approves-enlicitide-the-first-oral-pcsk9-inhibitor-for-high-cholesterol)
- American Journal of Managed Care (AJMC) (https://www.ajmc.com/view/fda-approves-enlicitide-first-oral-pcsk9-for-high-cholesterol)
- Medical Daily (https://www.medicaldaily.com/fda-approves-lipfendra-enlicitide-oral-pcsk9-inhibitor-cholesterol-2026-476197)
- BioSpace (Merck / competitive context) (https://www.biospace.com/fda/merck-dives-into-cholesterol-with-first-fda-approval-for-oral-pcsk9-inhibitor)